Benzodiazepine and related drug prescriptions have increased among young people in Sweden

August 7, 2018, Public Library of Science
Credit: CC0 Public Domain

The prevalence rate of prescriptions for benzodiazepines and benzodiazepine-related drugs (BZD)—medications used to treat anxiety, insomnia, epilepsy and other neuropsychiatric conditions—increased by 22% between 2006 and 2013 among individuals aged 0-24 years in Sweden, according to a study published this week in PLOS Medicine. The study, conducted by Anna Sidorchuk of the Karolinska Institutet, Stockholm, and colleagues, indicates that during these years in Sweden, BZD prescriptions to young people were usually accompanied by a prescription for another psychotropic medication, and were commonly prescribed for longer than 6 months.

BZD are among the most widely used psychotropic medications in the world, and may lead to dependence and adverse effects, in particular among long-term users. To explore usage among young people, which has been poorly characterized, the authors linked nationwide Swedish health and administrative registers on roughly 4 million young people living in Sweden between 2006-2013, among whom 17,500 children (0-11 years), 15,039 adolescents (12-17 years), and 85,200 young adults (18-24 years) were dispensed a BZD prescription at least once.

They found that the prevalence rate of BZD prescription increased from 0.81 per 100 inhabitants in 2006 to 0.99 per 100 inhabitants in 2013. Nearly 65% of the time, the first prescription was issued outside specialized psychiatric services. Most first originated from primary care (41%) and non-psychiatric specialist settings (24%) such as paediatrics and internal medicine. Over 75% of study participants were dispensed other concurrently with a BZD, raising concerns about the potential risk of drug interactions. And almost 30% were prescribed a BZD for longer than 6 months, contradicting international and national guidelines that advise against BZD use beyond 2-4 weeks for adults and generally discourage prescribing BZDs for ages below 18 years.

The study used , and cannot confirm actual BZD usage. However, these data suggest concerning patterns of BZD dispensation to young people in this setting. The authors state, "[t]here is a need for clinicians, particularly those working in non-psychiatric services, to implement strategies to avoid potentially harmful patterns of prescribing BZDs to ."

Explore further: Psychiatric medications are not overprescribed for kids, finds study

More information: Sidorchuk A, Isomura K, Molero Y, Hellner C, Lichtenstein P, Chang Z, et al. (2018) Benzodiazepine prescribing for children, adolescents, and young adults from 2006 through 2013: A total population register-linkage study. PLoS Med 15(8): e1002635. doi.org/10.1371/journal.pmed.1002635

Related Stories

Psychiatric medications are not overprescribed for kids, finds study

January 29, 2018
A new study at Columbia University Irving Medical Center (CUIMC) challenges the popular notion that psychiatric medications are overprescribed in children and adolescents in the U.S. When the researchers compared prescribing ...

Doctors in Germany prescribing more psychotropic drugs for children and adolescents

June 21, 2016
More prescriptions for psychotropic drugs in children and adolescents in Germany have been issued than in the past. This is the result of a study reported by Sascha Abbas and colleagues in the current issue of Deutsches Ärzteblatt ...

Despite risks, benzodiazepine use highest in older people

December 17, 2014
Prescription use of benzodiazepines—a widely used class of sedative and anti-anxiety medications—increases steadily with age, despite the known risks for older people, according to a comprehensive analysis of benzodiazepine ...

Psychotropic medication use, including stimulants, in young children leveling off

September 30, 2013
The use of psychotropic prescription medications to treat ADHD, mood disorders, anxiety and other mental health disorders in very young children appears to have leveled off.

Risky opioid prescriptions linked to higher chance of death

June 18, 2018
When patients are prescribed opioids in risky ways, their chance of dying increases and their odds of death go higher as the number of risky opioid prescriptions increase, according to a new RAND Corporation study.

Psychiatric diagnosis common in medicaid-insured children

May 4, 2018
(HealthDay)—About 20 percent of Medicaid-insured children receive a psychiatric diagnosis by age 8 years, according to a study published online April 30 in JAMA Pediatrics.

Recommended for you

Shortcut strategy for screening compounds with clinical potentials for drug development

December 4, 2018
Developing a new drug often takes years and costs hundreds of millions of dollars. A shortcut has now been reported in a study led by City University of Hong Kong (CityU), which can potentially reduce the time and costs of ...

Drug wholesalers drove fentanyl's deadly rise, report concludes

December 4, 2018
Fentanyl, a powerful synthetic opioid implicated in nearly 29,000 overdose deaths in the United States last year, most likely spread because of heroin and prescription pill shortages, and also because it was cheaper for drug ...

Global review reports on administration of children's antibiotics

December 4, 2018
Researchers analyzing the sales of oral antibiotics for children in 70 high- and middle-income countries found that consumption varies widely from country to country with little correlation between countries' wealth and the ...

Opioid prescriptions from dentists linked to youth addiction risk

December 3, 2018
Teens and young adults who receive their initial opioid prescriptions from their dentists or oral surgeons are at increased risk for opioid addiction in the following year, a study from the Stanford University School of Medicine ...

Rise in meth and opioid use during pregnancy

November 29, 2018
Amphetamine and opioid use in pregnancy increased substantially over the last decade in the United States, a new Michigan Medicine-led study finds. And a disproportionate rise occurred in rural counties.

Mouse model aids study of immunomodulation

November 19, 2018
Because mice do not respond to immunomodulatory drugs (IMiDs), preclinical therapeutic and safety studies of the effects of IMiDs have not been possible in existing types of mice. This has led to an inability to accurately ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.